Xeris Biopharma: Record Quarter, Debt-Free Balance Sheet, and a Blockbuster Pipeline Milestone

Xeris Biopharma's second-quarter 2026 earnings call delivered more than just record revenue — it signaled a definitive shift in the company's financial and strategic trajectory. With total revenue of $92 million, a 34% year-over-year increase, and the full retirement of its convertible notes, the company is clearly entering a new phase. The stock has responded, surging 48.7% in the last 90 days, a reflection of growing investor confidence in the execution of its three stated priorities: rapid revenue growth, pipeline advancement, and disciplined capital allocation.

Record Quarter and Guidance Raise

The commercial portfolio is firing on all cylinders. “Total revenue reached $92 million with net product revenue of $91 million, representing 34% growth year-over-year.” — John Shannon, Chairman and Chief Executive Officer · 2026-08-06 Recorlev, the flagship product for endogenous Cushing's syndrome, continued its exceptional momentum, with “net revenue increased to nearly $57 million in the quarter, representing 81% growth year-over-year.” — John Shannon, Chairman and Chief Executive Officer · 2026-08-06 The company's commercial momentum is not just a one-quarter phenomenon; it is being driven by record numbers of new patient starts, referrals, and prescribers. Management raised the bottom end of full-year revenue guidance to $385–390 million, a testament to their conviction. As CFO Steven Pieper stated, “We are raising the bottom end of our full year 2026 total revenue guidance to $385 million to $390 million.” — Steven Pieper, Chief Financial Officer · 2026-08-06 This raise builds on prior guidance philosophy; as John Shannon noted in the Q1 call, the expansion benefit typically takes 6–9 months to fully hit stride, “We know from prior experience, this takes 6 to 9 months for them to really fully hit stride.” — John Shannon, Chief Executive Officer · 2026-05-07 The second half is expected to benefit from incremental contributions as the expanded sales force matures.

The blended revenue trajectory is steep and accelerating, yet the company is also showing improving operating leverage. Adjusted EBITDA grew over 50% year-over-year to $19.3 million, and management reiterated its commitment to remain adjusted EBITDA positive, echoing a previous promise: “We will remain adjusted EBITDA positive going forward.” — Steven Pieper, Chief Financial Officer (CFO) · 2025-11-06

A Cleaner Balance Sheet

The most striking strategic change this quarter was the full retirement of the company's convertible notes. Completed in July, the transaction eliminated $34 million of debt and approximately $3 million in annual interest expense. The exchange triggered a one-time non-cash charge of ~$31 million, but this is a small price for a significantly simplified capital structure. This is a new theme for Xeris; the keyword convertible note now tops the company's momentum chart, reflecting the market's attention on this de-risking event.

We are not going to start that Phase III trial till we have the go-to-market commercial presentation ready.

XP-8121: The Next Growth Engine

Hand-in-hand with the balance sheet cleanup, Xeris is advancing its most important pipeline asset, XP-8121, a once-weekly subcutaneous levothyroxine for hypothyroidism. The program is on track to start a Phase III trial by year-end, and the company will host a dedicated webinar on September 9 to outline the full program, including trial design and regulatory timelines. Management has consistently emphasized that they will not compromise on commercial readiness, reflecting a disciplined approach to development. The XP-8121 program is a potential blockbuster, addressing a multi-billion-dollar opportunity. The company has also strengthened its intellectual property estate with new patents, reinforcing its competitive moat.

This focus on pipeline advancement is a notable evolution from prior quarters, where the conversation centered more on Recorlev's commercial expansion and IP litigation. While those remain important, the emergence of XP-8121 program as a concrete catalyst adds a new layer to the investment thesis.

Keveyis IP and a Durable Portfolio

Beyond Recorlev and XP-8121, the company continues to extract value from its mature brands. Keveyis delivered approximately $12 million in revenue, and the recent notice of allowance for a new patent extending protection to at least 2039 is a significant win. This protection for Keveyis allows Xeris to invest incrementally in the PPP community, confident that the brand can sustain its remarkable durability. The commercial portfolio is increasingly diversified, and the company's commercial team is executing well across all fronts.

In summary, Xeris Biopharma's Q2 2026 was a watershed. Record revenue, a strengthened balance sheet, and a clear path for the pipeline have combined to put the company on a fundamentally stronger footing. The market is rewarding this progress, and with XP-8121's upcoming program overview, the next few months could be catalyst-rich. The company is executing on multiple fronts, and the story is far from over.